Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 8/20 | 0.45 |
| ▸ | FAP | Q12884 | 4/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17347050 | 1.00 | DPP7 (0.46) | DPP7KDM4EDPP4FAPEPHX1 | |
| SCHEMBL991936 | 0.98 | DPP4 (0.43) | DPP7KDM4EDPP4FAPEPHX1 | |
| Hydrochloric Acid SCHEMBL3512222 | 0.95 | ALDH1A1 (0.44) | DPP7KDM4EDPP4FAPEPHX1 | |
| SCHEMBL11922743 | 0.93 | — | — | |
| SCHEMBL1908528 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL2715582 | 0.86 | — | — | |
| SCHEMBL3769999 | 0.80 | KDM1A (0.40) | DPP7DPP4FAPALDH1A1HPGD | |
| SCHEMBL750354 | 0.80 | METAP1 (0.40) | DPP7DPP4 | |
| SCHEMBL994220 | 0.80 | EPHX2 (0.46) | DPP7DPP4FAPCYP3A4EPHX2 | |
| SCHEMBL6127326 | 0.80 | EPHX2 (0.46) | DPP7DPP4FAPCYP3A4EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102471339-A | Pyrrolopyridine inhibitors of kinases | ABBOTT LAB | 2012-05-23 | — | — | CN | claimed |
| WO-2011008915-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | claimed |
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | claimed |
| US-20090042880-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2009-02-12 | — | — | US | claimed |
| CN-114805352-B | Pyrrolopyridine substituted fused quinoline compounds as PI3K/MTOR inhibitors | 南京爱德程医药科技有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-114790207-B | Substituted pyridinyl substituted fused quinoline compounds as PI3K/MTOR inhibitors | 南京爱德程医药科技有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-114805351-B | Amido-bearing pyridyl-substituted fused quinoline compounds as PI3K/MTOR inhibitors | 南京爱德程医药科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-109121414-A | Benzopyrazole compounds and analogs thereof | 拜奥克里斯特制药公司 | 2019-01-01 | — | — | CN | disclosed |
| EP-3275861-A1 | TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| EP-2470500-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9624166-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
| US-20040122244-A1 | Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1314712-A1 | NF-KAPPA-B INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT | Daiichi Suntory Pharma Co., Ltd. (JP) | 2003-05-28 | — | — | EP | disclosed |
| US-5948780-A | ADMINISTERING A METALLOPROTEINASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| US-5672615-A | MATRIX-DEGRADING METALLOPROTEINASE INHIBITORS | NOVARTIS CORPORATION (US) | 1997-09-30 | — | — | US | disclosed |
| US-4690925-A | ANTITHROMBOTIC ACTIVITY, CARDIOTONIC AGENTS | SYNTEX (U.S.A.) INC. (US) | 1987-09-01 | — | — | US | disclosed |
| EP-0153152-A2 | (2-Oxo-1,2,3,5-tetrahydroimidazo-/2,1-b/quinnazolinyl)-oxyalkylamides, their preparation, compositions containing them and their use in making medicaments | SYNTEX (U.S.A.) INC. (US) | 1985-08-28 | — | — | EP | disclosed |
| EP-0061623-A1 | Process for dyeing or printing paper, and cationic phthalocyanine dyes | BASF Aktiengesellschaft (DE) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122244-A1 | Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient | NFKBIA, NFKB1, IKBKB | DPP7 3143/4885KDM4E 1491/4885DPP4 4097/4885 |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | C5, ADRA2C, ADRA1A | DPP7 1443/4885KDM4E 3541/4885DPP4 1871/4885 |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1A, TUBA1C | DPP7 1641/4885KDM4E 2659/4885DPP4 1480/4885 |
| US-20090042880-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | CDK2, CDK1, CDK4 | DPP7 1689/4885KDM4E 756/4885DPP4 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.